Date:2/6/2009

rom deferred government incentives 102,401 18,701 102,401 49,965 Proceeds from government assistance 143,339 - 776,431 - Payment of financing fees - debt (11,036) - (11,036) - Proceeds from revolving credit facility 8,591,273 8,505,017 16,976,011 13,451,976 Repayment of revolving credit facility (7,146,912) (5,281,835) (13,266,396) (10,380,520) Repayment of capital lease obligations (71,345) (29,164) (130,025) (64,323) Repayment of senior and other long-term debt (137,844) (4,861) (170,989) (9,612) ------------------------------------------------------------------------- Cash provided by financing activities 1,469,876 3,207,858 4,276,397 3,047,486 ------------------------------------------------------------------------- Net increase (decrease) in cash and cash equivalents during the period 1,352,524 (1,364,406) 1,236,184 5,116,350 Cash and cash equivalents, beginning of period 4,282,725 8,004,353 4,399,065 1,523,597 ------------------------------------------------------------------------- Cash and cash equivalents, end of period 5,635,249 6,639,947 5,635,249 6,639,947 ------------------------------------------------------------------------- -------------------------------------------------------------------------

'/>"/>

SOURCE Bioniche Life Sciences Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
3. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
4. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
5. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
6. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Bioniche Reports Fiscal 2008 First Quarter
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
11. Bioniche Reports Fiscal 2008 Second Quarter